HEXAGON COMPOSITES WKN: 904953 ISIN: NO0003067902 Kürzel: HEX Forum: Aktien Thema: Hauptdiskussion
20 August 2024 - Oslo, Norway: Hexagon Composites ASA ("Hexagon" or the "Company") has retained DNB Markets, a part of DNB Bank ASA as sole bookrunner (the "Manager") to advise on and effect a private placement of new ordinary shares in the Company (the "Offer Shares") to raise gross proceeds of NOK 300 million (the "Private Placement"). The subscription price per Offer Share in the Private Placement (the "Subscription Price") will be determined by the Company's Board of Directors (the "Board") on the basis of an accelerated book-building process conducted by the Manager. The net proceeds from the Private Placement will be used to (i) secure flexibility to execute specific near-term synergetic acquisition opportunities, (ii) increase working capital to support the planned strong growth in Hexagon Agility, (iii) maintain ability to support Hexagon Purus, (iv) keep long-term net interest-bearing debt below 3x LTM EBITDA “steady state” as previously communicated, and (v) for general corporate purposes.
|
Thema | ||
---|---|---|---|
1 | Nio für normale Kommunikation | ±0,00 % | |
2 | Trading- und Aktien-Chat | ||
3 | BURBERRY Hauptdiskussion | ±0,00 % | |
4 | News - InnoCan Pharma Aktie | ±0,00 % | |
5 | Vestas | ±0,00 % | |
6 | MICROSTRATEGY Hauptdiskussion | ±0,00 % | |
7 | ATOS Hauptdiskussion | ±0,00 % | |
8 | Palantir | +0,85 % | |
9 | für alle, die es ehrlich meinen beim Traden. | ||
10 | RENK (für normale, sachliche Kommunikation!) | ±0,00 % | Alle Diskussionen |
|
Thema | ||
---|---|---|---|
1 | Nio für normale Kommunikation | ±0,00 % | |
2 | BURBERRY Hauptdiskussion | ±0,00 % | |
3 | Vestas | ±0,00 % | |
4 | MICROSTRATEGY Hauptdiskussion | ±0,00 % | |
5 | ATOS Hauptdiskussion | ±0,00 % | |
6 | Palantir | +0,85 % | |
7 | News - InnoCan Pharma Aktie | ±0,00 % | |
8 | MICRON TECHNOLOGY Hauptdiskussion | +0,53 % | |
9 | BioNTech Hauptdiskussion | ±0,00 % | |
10 | GAMESTOP Hauptdiskussion | +0,94 % | Alle Diskussionen |